ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2026
Endovascular revascularization for treatment of acute mesenteric ischemia: a single-center experience.
Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute mesenteric ischemia (AMI), primarily from superior mesenteric artery (SMA) occlusion, is a life-threatening condition with high mortality. While open surgery has been the standard, endovascular techniques are emerging as a less invasive alternative. Aim: This study evaluated the outcomes of an endovascular-first strategy for AMI. Material and methods: A single-center, retrospective analysis was conducted on 25 consecutive patients (median age 74) with AMI due to SMA occlusion (23 thrombotic, 2 embolic) treated between 2022 and 2025. All patients underwent endovascular recanalization via antegrade or retrograde techniques, using stents, aspiration thrombectomy, or hybrid procedures as needed. The primary endpoint was a composite of mortality or irreversible bowel ischemia requiring resection. Results: Technical success was achieved in 24 (96%) patients. The in-hospital mortality rate was 16%. The cumulative 30-day rate of major adverse events was 24%. Serum lactate proved to be a sensitive marker for bowel viability, normalizing only in patients without necrosis. No recurrent stenosis was observed at 3- and 6-month follow-up. Conclusions: An endovascular-first approach for AMI is feasible, safe, and effective, with high technical success and acceptable mortality. It is applicable to both thrombotic and embolic occlusions. Success requires a multidisciplinary strategy, advanced endovascular tools, and the capability to convert to open surgery. The prognosis ultimately depends on the extent of bowel necrosis, underscoring the critical need for rapid diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.